Stockscreener 앱 받기
67.53
2.07%
1.37
시간 외 거래:
66.97
-0.56
-0.83%
전일 마감가:
$66.16
열려 있는:
$66.04
하루 거래량:
1.55M
Relative Volume:
0.73
시가총액:
$12.30B
수익:
$381.03M
순이익/손실:
$-1.01B
주가수익비율:
-11.35
EPS:
-5.95
순현금흐름:
$-789.25M
1주 성능:
-0.87%
1개월 성능:
-4.62%
6개월 성능:
-7.68%
1년 성능:
+186.14%
1일 변동 폭
$65.56
$67.65
1주일 범위
$64.84
$68.99
52주 변동 폭
$21.92
$84.91
Insmed Inc Stock (INSM) Company Profile
명칭
Insmed Inc
전화
908-977-9900
주소
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
INSM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
67.53 | 12.41B | 381.03M | -1.01B | -789.25M | -5.95 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-13 | 개시 | Jefferies | Buy |
| 2025-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2024-04-23 | 개시 | Truist | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-07-26 | 개시 | Guggenheim | Buy |
| 2022-12-09 | 개시 | Mizuho | Buy |
| 2022-12-07 | 개시 | Barclays | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Buy |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2021-12-06 | 개시 | JP Morgan | Overweight |
| 2021-10-19 | 재개 | Monness Crespi & Hardt | Buy |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-10-12 | 재개 | Stifel | Buy |
| 2019-09-03 | 개시 | Goldman | Buy |
| 2019-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-15 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-01-02 | 개시 | Canaccord Genuity | Buy |
| 2018-08-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | 개시 | Goldman | Neutral |
| 2018-04-23 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | 개시 | Morgan Stanley | Overweight |
| 2018-01-18 | 개시 | Credit Suisse | Neutral |
| 2017-09-05 | 재확인 | Evercore ISI | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-11 | 개시 | Robert W. Baird | Outperform |
| 2016-03-15 | 개시 | Stifel | Buy |
| 2015-11-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2015-10-06 | 재확인 | H.C. Wainwright | Buy |
| 2015-06-09 | 개시 | Citigroup | Neutral |
| 2014-03-26 | 재확인 | HC Wainwright | Buy |
모두보기
Insmed Inc 주식(INSM)의 최신 뉴스
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.
Insmed Says Brensocatib Showed Consistent Efficacy in Non-Cystic Fibrosis Bronchiectasis - marketscreener.com
Insmed (INSM) Highlights Promising Brensocatib Trial Results at - GuruFocus
Insmed (INSM) Highlights Promising Brensocatib Trial Results at ATS 2025 | INSM Stock News - GuruFocus
Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study - Yahoo Finance
Captrust Financial Advisors Sells 631 Shares of Insmed Incorporated (NASDAQ:INSM) - Defense World
Mercer Global Advisors Inc. ADV Acquires New Position in Insmed Incorporated (NASDAQ:INSM) - Defense World
HC Wainwright Issues Optimistic Outlook for Insmed Earnings - Defense World
INSMED Executives Sell Shares to Satisfy Tax Obligations - TradingView
Jefferies Financial Group Initiates Coverage on Insmed (NASDAQ:INSM) - Defense World
Jefferies Initiates Coverage of Insmed (BIT:1INSM) with Buy Recommendation - Nasdaq
Insmed Incorporated (INSM): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
Jefferies Initiates Coverage of Insmed (BMV:INSM) with Buy Recommendation - Nasdaq
Jefferies sets $105 target on Insmed stock with Buy rating By Investing.com - Investing.com Nigeria
Insmed at Bank of America 2025 Healthcare Conference: Strategic Pipeline Focus - Investing.com
Jefferies Initiates Coverage on INSM with a Buy Rating and $105 PT | INSM Stock News - GuruFocus
Jefferies Initiates Coverage of Insmed (LSE:0JAV) with Buy Recommendation - Nasdaq
Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Jefferies Initiates Coverage of Insmed (INSM) with Buy Recommendation - Nasdaq
Jefferies Initiates Coverage on Insmed With Buy Rating, $105 Price Target - marketscreener.com
Jefferies sets $105 target on Insmed stock with Buy rating - Investing.com
Insmed (NASDAQ:INSM) Given Buy Rating at HC Wainwright - Defense World
Insmed (INSM) Gains Buy Rating from Jefferies with Promising Out - GuruFocus
Insmed (INSM) Receives Reaffirmed Buy Rating from HC Wainwright - GuruFocus
Analyst Expectations For Insmed's Future - Benzinga
Insmed Incorporated (NASDAQ:INSM) Given Consensus Rating of “Buy” by Analysts - Defense World
UBS Group Cuts Insmed (NASDAQ:INSM) Price Target to $109.00 - Defense World
Analysts Are Updating Their Insmed Incorporated (NASDAQ:INSM) Estimates After Its First-Quarter Results - Yahoo Finance
Insmed Incorporated (NASDAQ:INSM) Q1 2025 Earnings Call Transcript - Insider Monkey
Insmed (INSM) Receives Slight Price Target Adjustment by UBS | I - GuruFocus
UBS Maintains Buy Rating, Lowers Price Target for Insmed (INSM) - GuruFocus
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates - TradingView
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Benzinga
Is Insmed Incorporated (INSM) the Best Cancer Stock to Invest in for Long-Term Gain? - Insider Monkey
Insmed (INSM) Receives Slight Price Target Adjustment by UBS | INSM Stock News - GuruFocus
RBC Trims Price Target on Insmed to $99 From $100, Keeps Outperform Rating - marketscreener.com
Insmed: Q1 Earnings Snapshot - Greenwich Time
Decoding Insmed Inc (INSM): A Strategic SWOT Insight - GuruFocus
Insmed’s Earnings Call: Strong Growth and Optimistic Outlook - TipRanks
Insmed Q1 2025 Earnings Call Transcript - MarketBeat
Transcript : Insmed Incorporated, Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Earnings call transcript: Insmed Q1 2025 shows mixed results with slight EPS miss - Investing.com
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Insmed Q1 Net Loss Widens, Revenue Increases; 2025 Revenue Guidance Maintained - marketscreener.com
Insmed (INSM) Reports Q1 Revenue Surpassing Expectations and Awaits Key Approvals | INSM Stock News - GuruFocus
Insmed Q1 2025 slides: ARIKAYCE sales surge 23% as brensocatib launch approaches - Investing.com
Insmed earnings missed by $0.07, revenue topped estimates - Investing.com
Insmed Inc (INSM) Q1 2025 Earnings: Revenue Hits $92.8 Million, Surpassing Estimates - GuruFocus
Insmed Inc (INSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
17.27%
1.06%
자본화:
|
볼륨(24시간):